Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Mendus (OMX: IMMU) – VITAL-CML clears first safety hurdle >

Arron Aatkar, PhD | Healthcare | Comment | 2 days ago

OSE Immunotherapeutics (PAR: OSE) – VEL-101 moves into Phase II in kidney transplantation >

Arron Aatkar, PhD | Healthcare | Comment | 2 days ago

SEE ALL COMMENTARY >

Elicera Therapeutics (ELIC)

Latest price

SEK2.88

▾ 0.16 (5.69)

As at 11/09/2026

Market capitalisation: SEK193m

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: The cost of insecure infrastructure

Have autos hit the brakes too hard?

The investment story needs to be seen

Audiovisual

Latest

KOL event – Lusvertikimab and the IL-7R pathway: An expert deep dive into IBD

Noctiluca in 60 seconds

Bull, Bear & Beyond – SynAct Pharma: executive interview

About Edison

Corporates

Investors

Careers

Healthcare Equities

Elicera Therapeutics (ELIC)

SEK2.88

Elicera Therapeutics — Positioned to deliver in cell and gene therapies

See morecontent on

Ernexa Therapeutics (ERNA)

USD4.17

Ernexa Therapeutics — On the path to the clinic

See morecontent on

ExpreS2ion Biotech (EXPRS2)

SEK1.25

ExpreS2ion Biotech — Building the clinical data package

See morecontent on

Genedrive (GDR)

GBP0.01

Genedrive — Point-of-care diagnostics driving rapid care decisions

See morecontent on

Herantis Pharma (HRTIS)

EUR1.47

Herantis Pharma — H126 results reflect Phase II preparations

Herantis Pharma — FDA feedback clears HER-096 Phase IIa path

Herantis Pharma – equity proposition

See morecontent on

Hyloris Pharmaceuticals (HYL)

EUR4.25

Immix Biopharma (IMMX)

USD12.14

Immix Biopharma — Q226: funded to execute its CAR-T strategy

Immix Biopharma – equity proposition

Immix Biopharma — Improved NEXICART-2 data; runway extends

See morecontent on

Kooth (KOO)

GBP1.85

Kooth — Soluna embeds as renewal risk recedes

Bull, Bear & Beyond – Kooth: executive interview

Kooth – executive interview

See morecontent on

LTR Pharma (LTP)

AUD0.46

LTR Pharma — Sizable upside potential for intranasal delivery

See morecontent on

Mendus (IMMU)

SEK7.18

Mendus — Positive CML safety readout supports strategy

Mendus — Clinical momentum builds into H226

Mendus — CML programme gathering pace; Q226 results

See morecontent on

MindMaze Therapeutics (MMTX)

CHF0.17

MindMaze Therapeutics — Organisational simplification supports way forward

MindMaze Therapeutics – equity proposition

MindMaze Therapeutics — Vibra channel partnership expands US commercial footprint

See morecontent on

Newron Pharmaceuticals (NWRN)

CHF11.34

Newron Pharmaceuticals — Strengthened funding ahead of pivotal readout

Newron Pharmaceuticals — Pivotal readout moves firmly into view

Newron Pharmaceuticals – equity proposition

See morecontent on

Ocugen (OCGN)

USD1.02

Ocugen — Novel cell therapies for retinal diseases

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on